Innit Spins Off AI Venture to Provide Text Support for Weight-Loss Patients
Amsterdam, Tuesday 24 March 2026
Food tech firm Innit has launched Kind Intelligence Foundry to provide ‘Glo’, an innovative text-based AI companion supporting patients navigating weight-loss medications like Ozempic between doctor visits.
Addressing the Support Gap with Artificial Intelligence
On 24 March 2026, the food technology firm Innit formally announced the spin-off of Kind Intelligence Foundry, an independent venture dedicated to direct-to-consumer digital health [1]. The new entity’s flagship product, Glo, is an SMS-based artificial intelligence companion designed for individuals taking GLP-1 medications, including Ozempic, Wegovy, Zepbound, and Mounjaro [1]. The application, currently available in an alpha testing phase at askglo.ai, aims to bridge the communication gap patients often experience between medical appointments [1]. The venture is led by Chief Executive Officer Stathis Mytilinaios, who previously spearheaded the development of a Type 2 diabetes application named Phil in collaboration with Roche during his tenure at Innit [1]. Mytilinaios brings substantial experience to the role, having been part of the founding team at Livongo Health, a company eventually acquired by Teladoc Health for $18.5 billion [1].
Automating the Healthcare Revenue Cycle and Clinical Infrastructure
Beyond consumer-facing applications, artificial intelligence is increasingly being embedded into the foundational workflows of European healthcare systems [2]. A prime example is Parallel, a Paris-based firm that recently secured $20 million in Series A funding led by Index Ventures [2]. This capital injection represents a significant 471.429 per cent increase in funding from its $3.5 million seed round raised less than a year prior [2]. The capital is earmarked for expanding the deployment of AI agents across hospital administration [2]. Rather than replacing existing systems, Parallel’s technology operates as an overlay to automate the revenue cycle layer—specifically medical coding and billing—ensuring that hospitals receive accurate and timely payments [2]. This reflects a broader industry shift where value is generated within essential operational workflows rather than at the periphery of healthcare systems [2].
Industry Consolidation and the Growing Cyber Risk
As digital integration deepens, the broader medical technology market is experiencing significant consolidation [2]. On 23 March 2026, Abbott closed its acquisition of Exact Sciences in a transaction valued at approximately $19.84 billion [2] [alert! ‘The source questions the exact regulatory status of this closing, marking it with a deadline check’]. This strategic expansion is anticipated to generate roughly $3 billion in incremental sales by the end of 2026, although the meaningful contribution of European markets will depend heavily on reimbursement strategies across various health technology assessment bodies, such as the National Institute for Health and Care Excellence (NICE) in the United Kingdom [2]. Furthermore, regulatory milestones continue to shape the landscape, with the US Food and Drug Administration (FDA) granting approval on 18 March 2026 for JenaValve’s Trilogy Transcatheter Heart Valve System, a technology that has already been utilised in over 1,200 procedures across Europe since receiving its CE Mark in 2021 [2].